Galderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis Press release
CHMP recommends approval of Galderma’s nemolizumab for moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union Press release
Galderma’s phase III OLYMPIA 1 data published in JAMA Dermatology demonstrate that nemolizumab improves core signs and symptoms of prurigo nodularis Press release
Celebrating 25 years of Sculptra®: new data and recent approval in China cements Galderma’s leadership in regenerative biostimulation Press release
Galderma brings together over 650 healthcare professionals from Asia-Pacific to elevate knowledge of future aesthetic trends Press release
Galderma delivers record net sales of 3.259 B USD in the first nine months of 2024, demonstrates significant innovation progress, confirms and narrows its full year net sales guidance Press release
ASDS 2024: new phase III READY-4 data demonstrate long-term safety and efficacy of Galderma’s RelabotulinumtoxinA (Relfydess™) Press release
EADV 2024 Late breaking news sessions: new Galderma data demonstrating nemolizumab’s long-term efficacy and safety in atopic dermatitis and durability in prurigo nodularis to be shared during three oral presentations Press release
